{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T04:47:10Z","timestamp":1782276430824,"version":"3.54.5"},"reference-count":65,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Mineralocorticoid receptor (MR) overactivation is a key driver of inflammation, fibrosis, and organ cross-talk across cardiorenal disease. Finerenone, a selective non-steroidal MR antagonist, has demonstrated robust renoprotective and cardioprotective benefits in patients with chronic kidney disease (CKD) and type 2 diabetes in large randomized clinical trials. Beyond its established role in diabetic kidney disease, emerging preclinical and clinical data suggest potential systemic effects through the attenuation of MR-driven inflammatory and fibrotic pathways. These include signals related to heart failure outcomes, atrial remodeling, pulmonary vascular biology, retinal microvascular integrity, and metabolic dysfunction. However, much of the evidence beyond established cardiorenal indications remains exploratory, based on preclinical studies, subgroup analyses, and post hoc evaluations. This review provides a critical synthesis of the established clinical evidence supporting finerenone in CKD and cardiovascular disease. It examines emerging, hypothesis-generating data regarding its potential systemic effects beyond diabetic kidney disease.<\/jats:p>","DOI":"10.3390\/jcm15134852","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T03:09:17Z","timestamp":1782270557000},"page":"4852","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Finerenone Beyond Diabetic Kidney Disease: Emerging Evidence and Potential Systemic Implications"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-7906-9788","authenticated-orcid":false,"given":"Mohanad","family":"Almaimani","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, College of Medicine, University of Jeddah, Jeddah 23218, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadin Ayman","family":"Alamri","sequence":"additional","affiliation":[{"name":"King Faisal Specialist Hospital and Research Center, Riyadh 11211, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"106541","DOI":"10.1016\/j.jsbmb.2024.106541","article-title":"The multifaceted role of the mineralocorticoid receptor in cancers","volume":"242","author":"Doan","year":"2024","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1146\/annurev-physiol-042022-015223","article-title":"The Mineralocorticoid Receptor in the Vasculature: Friend or Foe?","volume":"86","author":"Ibarrola","year":"2024","journal-title":"Annu. Rev. Physiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1124\/pr.115.011106","article-title":"Emerging Roles of the Mineralocorticoid Receptor in Pathology: Toward New Paradigms in Clinical Pharmacology","volume":"68","author":"Jaisser","year":"2016","journal-title":"Pharmacol. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.1111\/bph.15746","article-title":"Structural and molecular determinants of mineralocorticoid receptor signalling","volume":"179","author":"Grossmann","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/s00125-023-06031-1","article-title":"Mineralocorticoid receptor overactivation: Targeting systemic impact with non-steroidal mineralocorticoid receptor antagonists","volume":"67","author":"Savarese","year":"2024","journal-title":"Diabetologia"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.kisu.2021.11.004","article-title":"Nonepithelial mineralocorticoid receptor activation as a determinant of kidney disease","volume":"12","author":"Nakamura","year":"2022","journal-title":"Kidney Int. Suppl."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1161\/01.HYP.0000255636.11931.a2","article-title":"Podocyte as the Target for Aldosterone","volume":"49","author":"Shibata","year":"2007","journal-title":"Hypertension"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/nrneph.2013.110","article-title":"Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis","volume":"9","author":"Brown","year":"2013","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1007\/s00125-004-1542-0","article-title":"Aldosterone escape during blockade of the renin?angiotensin?aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate","volume":"47","author":"Schjoedt","year":"2004","journal-title":"Diabetologia"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"T125","DOI":"10.1530\/JOE-16-0600","article-title":"30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development","volume":"234","author":"Kolkhof","year":"2017","journal-title":"J. Endocrinol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Kawanami, D., Takashi, Y., Muta, Y., Oda, N., Nagata, D., Takahashi, H., and Tanabe, M. (2021). Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.754239"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1111\/bph.15747","article-title":"Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease","volume":"179","author":"Kintscher","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","article-title":"Finerenone, a Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Protects From Rat Cardiorenal Injury","volume":"64","author":"Kolkhof","year":"2014","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Zhai, S., Ma, B., Chen, W., and Zhao, Q. (2024). A comprehensive review of finerenone\u2014A third-generation non-steroidal mineralocorticoid receptor antagonist. Front. Cardiovasc. Med., 11.","DOI":"10.3389\/fcvm.2024.1476029"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"102946","DOI":"10.1016\/j.redox.2023.102946","article-title":"Non-steroidal mineralocorticoid receptor antagonist finerenone ameliorates mitochondrial dysfunction via PI3K\/Akt\/eNOS signaling pathway in diabetic tubulopathy","volume":"68","author":"Yao","year":"2023","journal-title":"Redox Biol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1161\/HYPERTENSIONAHA.116.08526","article-title":"Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Protects Against Acute Kidney Injury\u2013Mediated Chronic Kidney Disease","volume":"69","author":"Lattenist","year":"2017","journal-title":"Hypertension"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: The FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa2512854","article-title":"Finerenone in Type 1 Diabetes and Chronic Kidney Disease","volume":"394","author":"Heerspink","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"sfaf305","DOI":"10.1093\/ckj\/sfaf305","article-title":"Dosing, treatment patterns and safety of finerenone use in routine care: An interim analysis of the prospective, real-world and observational FINE-REAL study","volume":"18","author":"Wheeler","year":"2025","journal-title":"Clin. Kidney J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"sfad285","DOI":"10.1093\/ckj\/sfad285","article-title":"Optimization of guideline-directed medical therapies in patients with diabetes and chronic kidney disease","volume":"17","author":"Neumiller","year":"2024","journal-title":"Clin. Kidney J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJMoa2410659","article-title":"Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes","volume":"393","author":"Agarwal","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/S0140-6736(18)32279-7","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990\u20132017: A systematic analysis for the Global Burden of Disease Study 2017","volume":"392","author":"James","year":"2018","journal-title":"Lancet"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/S0140-6736(16)32064-5","article-title":"Chronic Kidney Disease","volume":"389","author":"Webster","year":"2017","journal-title":"Lancet"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Heerspink, H.J.L., Neuen, B.L., Agarwal, R., Cherney, D.Z.I., Lam, C.S.P., Tuttle, K.R., Wanner, C., Sarafidis, P., Jongs, N., and Smeijer, J.D. (2026). Finerenone in Persons with Chronic Kidney Disease without Diabetes. N. Engl. J. Med., Epub ahead of print.","DOI":"10.1056\/NEJMoa2604625"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1161\/HYPERTENSIONAHA.117.10360","article-title":"Selective Mineralocorticoid Receptor Cofactor Modulation as Molecular Basis for Finerenone\u2019s Antifibrotic Activity","volume":"71","author":"Grune","year":"2018","journal-title":"Hypertension"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1161\/HYPERTENSIONAHA.114.04488","article-title":"Mineralocorticoid Receptor Activation and Mineralocorticoid Receptor Antagonist Treatment in Cardiac and Renal Diseases","volume":"65","author":"Bauersachs","year":"2015","journal-title":"Hypertension"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Blankenburg, M., Fett, A.K., Eisenring, S., Haas, G., and Gay, A. (2019). Patient characteristics and initiation of mineralocorticoid receptor antagonists in patients with chronic kidney disease in routine clinical practice in the US: A retrospective cohort study. BMC Nephrol., 20.","DOI":"10.1186\/s12882-019-1348-4"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","article-title":"A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease","volume":"37","author":"Filippatos","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Peng, S., Li, P., Yu, Z., Du, B., and Yang, P. (2025). A systematic review and meta-analysis on the efficacy and safety of finerenone in the progression of heart failure. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1575307"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1093\/eurheartj\/ehr266","article-title":"Aldosterone promotes atrial fibrillation","volume":"33","author":"Reil","year":"2012","journal-title":"Eur. Heart J."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"6656","DOI":"10.1074\/jbc.M113.519256","article-title":"The Mineralocorticoid Receptor Promotes Fibrotic Remodeling in Atrial Fibrillation","volume":"289","author":"Lavall","year":"2014","journal-title":"J. Biol. Chem."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.bcp.2019.07.001","article-title":"The non-steroidal mineralocorticoid receptor antagonist finerenone prevents cardiac fibrotic remodeling","volume":"168","author":"Lavall","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jacc.2021.04.079","article-title":"Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes","volume":"78","author":"Filippatos","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/j.jacc.2025.03.429","article-title":"Finerenone Reduces New-Onset Atrial Fibrillation Across the Spectrum of Cardio-Kidney-Metabolic Syndrome","volume":"85","author":"Pabon","year":"2025","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: A randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur. Heart J."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Mamazhakypov, A., and Lother, A. (2023). Therapeutic targeting of mineralocorticoid receptors in pulmonary hypertension: Insights from basic research. Front. Cardiovasc. Med., 10.","DOI":"10.3389\/fcvm.2023.1118516"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1161\/HYPERTENSIONAHA.122.19207","article-title":"Mineralocorticoid Receptor Antagonism by Finerenone Attenuates Established Pulmonary Hypertension in Rats","volume":"79","author":"Tu","year":"2022","journal-title":"Hypertension"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/20458940211025240","article-title":"Vascular cell-specific roles of mineralocorticoid receptors in pulmonary hypertension","volume":"11","author":"Menon","year":"2021","journal-title":"Pulm. Circ."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1161\/HYPERTENSIONAHA.121.17505","article-title":"MR (Mineralocorticoid Receptor) in Endothelial Cells: A Major Contributor in Pulmonary Arterial Hypertension Remodeling","volume":"78","author":"Jaisser","year":"2021","journal-title":"Hypertension"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Masarone, D., Valente, F., Verrengia, M., Contaldi, C., di Palma, V., Falco, L., Catapano, D., and di Lorenzo, E. (2024). Pharmacologic Treatment of Pulmonary Hypertension Due to Heart Failure with Preserved Ejection Fraction: Are There More Arrows on Our Bow?. J. Clin. Med., 13.","DOI":"10.3390\/jcm13226867"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s11906-025-01356-1","article-title":"Obstructive Sleep Apnea and Hypertension: Is Aldosterone Blockade the Optimal Approach to Control Blood Pressure and Improve Oxygenation?","volume":"28","author":"Ikeda","year":"2026","journal-title":"Curr. Hypertens. Rep."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Takeda, Y., Itaya-Hironaka, A., Yamauchi, A., Makino, M., Sakuramoto-Tsuchida, S., Ota, H., Kawaguchi, R., and Takasawa, S. (2021). Intermittent Hypoxia Upregulates the Renin and Cd38 mRNAs in Renin-Producing Cells via the Downregulation of miR-203. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms221810127"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Wang, Y., Li, C.X., Lin, Y.N., Zhang, L.Y., Li, S.Q., Zhang, L., Yan, Y.R., Lu, F.Y., Li, N., and Li, Q.Y. (2022). The Role of Aldosterone in OSA and OSA-Related Hypertension. Front. Endocrinol., 12.","DOI":"10.3389\/fendo.2021.801689"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/jhh.2009.96","article-title":"Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: A preliminary report","volume":"24","author":"Gaddam","year":"2010","journal-title":"J. Hum. Hypertens."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1002\/ejhf.3661","article-title":"Finerenone, Chronic Obstructive Pulmonary Disease, and Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the FINEARTS-HF Trial","volume":"27","author":"Butt","year":"2025","journal-title":"Eur. J. Heart Fail."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1161\/CIRCRESAHA.108.176008","article-title":"Identification of a Retinal Aldosterone System and the Protective Effects of Mineralocorticoid Receptor Antagonism on Retinal Vascular Pathology","volume":"104","author":"Tan","year":"2009","journal-title":"Circ. Res."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Jerome, J.R., Deliyanti, D., Suphapimol, V., Kolkhof, P., and Wilkinson-Berka, J.L. (2023). Finerenone, a Non-Steroidal Mineralocorticoid Receptor Antagonist, Reduces Vascular Injury and Increases Regulatory T-Cells: Studies in Rodents with Diabetic and Neovascular Retinopathy. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24032334"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1111\/dom.14915","article-title":"Effect of finerenone on the occurrence of vision-threatening complications in patients with non-proliferative diabetic retinopathy: Pooled analysis of two studies using routine ophthalmological examinations from clinical trial participants (ReFineDR\/DeFineDR)","volume":"25","author":"Rossing","year":"2023","journal-title":"Diabetes Obes. Metab."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"108411","DOI":"10.1016\/j.jdiacomp.2023.108411","article-title":"Design and rationale of FINE-REAL: A prospective study of finerenone in clinical practice","volume":"37","author":"Desai","year":"2023","journal-title":"J. Diabetes Complicat."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Kreiner, F.F., Schytz, P.A., Heerspink, H.J.L., von Scholten, B.J., and Idorn, T. (2023). Obesity-Related Kidney Disease: Current Understanding and Future Perspectives. Biomedicines, 11.","DOI":"10.3390\/biomedicines11092498"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1161\/HYPERTENSIONAHA.115.06642","article-title":"Leptin Induces Hypertension and Endothelial Dysfunction via Aldosterone-Dependent Mechanisms in Obese Female Mice","volume":"67","author":"Huby","year":"2016","journal-title":"Hypertension"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0952-3278(99)80020-9","article-title":"Plasma aldosterone, plasma lipoproteins, obesity and insulin resistance in humans","volume":"60","author":"Goodfriend","year":"1999","journal-title":"Prostaglandins Leukot. Essent. Fat. Acids"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1111\/jch.14898","article-title":"Obesity, aldosterone excess, and mineralocorticoid receptor activation: Parallel or intersected circumstances?","volume":"26","author":"Puzantian","year":"2024","journal-title":"J. Clin. Hypertens."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1186\/s12933-025-02935-x","article-title":"The mineralocorticoid receptor antagonist finerenone enhances cardiovascular recovery upon food intake normalization in obese mice","volume":"24","author":"Manon","year":"2025","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"sfaf157","DOI":"10.1093\/ckj\/sfaf157","article-title":"Efficacy and safety of finerenone in obesity-related glomerulopathy","volume":"18","author":"Qiu","year":"2025","journal-title":"Clin. Kidney J."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jacc.2024.10.111","article-title":"Finerenone, Obesity, and Heart Failure With Mildly Reduced\/Preserved Ejection Fraction","volume":"85","author":"Butt","year":"2025","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/dom.15305","article-title":"Efficacy of finerenone in patients with type 2 diabetes, chronic kidney disease and altered markers of liver steatosis and fibrosis: A FIDELITY subgroup analysis","volume":"26","author":"Perakakis","year":"2024","journal-title":"Diabetes Obes. Metab."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","article-title":"NAFLD: A multisystem disease","volume":"62","author":"Byrne","year":"2015","journal-title":"J. Hepatol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/13\/4852\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T04:00:20Z","timestamp":1782273620000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/13\/4852"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":65,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["jcm15134852"],"URL":"https:\/\/doi.org\/10.3390\/jcm15134852","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]}}}